Porcine reproductive and respiratory syndrome virus (PRRSV) inhibits the interferon-mediated antiviral response. Type I interferons (IFNs) induce the expression of IFN-stimulated genes by activating phosphorylation of both signal transducer and activator of transcription 1 (STAT1) and STAT2, which form heterotrimers (interferon-stimulated gene factor 3 [ISGF3]) with interferon regulatory factor 9 (IRF9) and translocate to the nucleus. PRRSV Nsp1␤ blocks the nuclear translocation of the ISGF3 complex by an unknown mechanism. In this study, we discovered that Nsp1␤ induced the degradation of karyopherin-␣1 (KPNA1, also called importin-␣5), which is known to mediate the nuclear import of ISGF3. Overexpression of Nsp1␤ resulted in a reduction of KPNA1 levels in a dose-dependent manner, and treatment of the cells with the proteasome inhibitor MG132 restored KPNA1 levels. Furthermore, the presence of Nsp1␤ induced an elevation of KPNA1 ubiquitination and a shortening of its half-life. Our analysis of Nsp1␤ deletion constructs showed that the N-terminal domain of Nsp1␤ was involved in the ubiquitinproteasomal degradation of KPNA1. A nucleotide substitution resulting in an amino acid change from valine to isoleucine at residue 19 of Nsp1␤ diminished its ability to induce KPNA1 degradation and to inhibit IFN-mediated signaling. Interestingly, infection of MARC-145 cells by PRRSV strains VR-2332 and VR-2385 also resulted in KPNA1 reduction, whereas infection by an avirulent strain, Ingelvac PRRS modified live virus (MLV), did not. MLV Nsp1␤ had no effect on KPNA1; however, a mutant with an amino acid change at residue 19 from isoleucine to valine induced KPNA1 degradation. These results indicate that Nsp1␤ blocks ISGF3 nuclear translocation by inducing KPNA1 degradation and that valine-19 in Nsp1␤ correlates with the inhibition.
P
orcine reproductive and respiratory syndrome virus (PRRSV) is an enveloped, positive-sense, single-stranded RNA virus belonging to the family Arteriviridae (1) . PRRSV is a significant issue to the swine industry across the world, and the virus-caused economic loss in the United States alone is estimated to be $560 million per year (2) . The PRRSV genome is a little over 15 kb in length and includes 10 open reading frames (ORFs) (3, 4) . ORFs 1a and 1b comprise 80% of the viral genome and encode nonstructural proteins, whereas ORFs 2 to 7 encode structural proteins (5, 6) . PRRSV propagation in vitro is mainly conducted in the epithelium-derived monkey kidney cell line MARC-145 (7) and in porcine pulmonary alveolar macrophages (PAMs). In its natural swine host, PRRSV targets mainly PAMs during its acute infection (8) .
PRRSV appears to inhibit the synthesis of type I interferons (IFNs) in infected pigs (9, 10) . IFNs could not be detected in the lungs of pigs in which PRRSV actively replicated. PRRSV infection of PAMs and MARC-145 cells in vitro leads to very low alpha interferon (IFN-␣) expression (9, 11) . The suppression of innate immunity can be an important contributing factor to the modulation of host immune responses. PRRSV infection in pigs leads to delayed production and low titers of neutralizing antibodies (12) , as well as a weak cell-mediated immune response (13) .
Type I IFNs, including IFN-␣ and IFN-␤, are critical to innate immunity against viral infections and play an important role in the stimulation of the adaptive immune response (14, 15) . The activation of IFN signaling leads to the induction of antiviral responses. The signaling of type I IFNs is initiated after they bind to their receptors on the cell surface (16) (17) (18) . This receptor binding activates Janus kinases (JAK), which then phosphorylate both signal transducer and activator of transcription 1 (STAT1) and STAT2. The phosphorylated STAT1 and STAT2 proteins form heterodimers which interact with interferon regulatory factor 9 (IRF9) and subsequently form heterotrimers, also known as interferon-stimulated gene factor 3 (ISGF3). Translocation of ISGF3 into the nucleus, followed by binding to consensus DNA sequences, leads to the expression of IFN-stimulated genes (ISGs). PRRSV inhibits the IFN-activated JAK/STAT signal transduction and expression of ISGs in both MARC-145 and PAM cells (19) . The nuclear translocation of ISGF3 is blocked in the PRRSV-infected cells, while the IFN-induced phosphorylation of STAT1 and STAT2 is minimally affected. PRRSV Nsp1␤ is able to block the nuclear translocation of ISGF3 complexes, yet the mechanism is unknown (19) .
In this study, we found that PRRSV Nsp1␤ induced degradation of karyopherin-␣1 (KPNA1), the karyopherin for ISGF3 nuclear translocation. HEK293 cells with Nsp1␤ expression had lower levels of KPNA1 protein. Infection of MARC-145 cells by PRRSV strains VR-2332 and VR-2385 resulted in the reduction of KPNA1 protein, while an avirulent strain, Ingelvac PRRS modi-fied live virus (MLV), did not. The addition of the proteasome inhibitor MG132 to the cells with Nsp1␤ expression restored the KPNA1 protein levels. The replacement of one nucleotide near the 5= terminus of VR-2385 Nsp1␤ diminished the protein's ability to reduce KPNA1 and to inhibit IFN-activated JAK/STAT signaling. Conversely, the replacement of the nucleotide at the same position near the 5= terminus of MLV Nsp1␤ caused a reduction of KPNA1. This discovery provides further insight into PRRSV interference with IFN-activated signaling.
MATERIALS AND METHODS
Cells and viruses. MARC-145 (7) and HEK293 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). PRRSV strains VR-2385 (20) , VR-2332 (21), and MLV (22) were used to inoculate MARC-145 cells at a multiplicity of infection (MOI) of 1. Virus titers for the median (50%) tissue culture infectious dose (TCID 50 ) were determined in MARC-145 cells as described previously (23) .
For interferon stimulation, recombinant human IFN-␣A/D (SigmaAldrich, St. Louis, MO) was added to the cultured cells at a final concentration of 1,000 U/ml (unless stated differently in Results and the figure legends). The cells were harvested at the time points indicated in Results or the figure legends for further analysis.
MG132 (Sigma), a proteosome inhibitor, was used to treat cells at 10 M final concentration for 6 h prior to the cells being harvested for further analysis. In order to determine the half-life of KPNA1, cycloheximide (Sigma) was added to cultured cells at a final concentration of 100 g/ml to block protein translation. The cells were harvested at the time points indicated in Results or the figure legends for Western blotting. Plasmids. The pEGFP-C1-STAT1 plasmid for STAT1-green fluorescent protein (GFP) expression was obtained from Addgene (24) . The pCAGGS-FLAG-KPNA1, -KPNA2, -KPNA3, and -KPNA4 plasmids were provided by M. L. Shaw (The Mount Sinai Hospital, New York, NY). The pCDNA3-Ubiquitin-Myc plasmid was provided by X. Zhu (The University of Maryland, College Park, MD). The cDNA sequences of Nsp1␤ were amplified from cDNA of strains VR-2385, VR-2332, and MLV with primers 85nsp1F2 and 85nsp1R2 (19) and were cloned separately into the pCAGEN-HA vector. Fragments of deletion constructs of VR-2385 Nsp1␤ were amplified with primers 85nsp1F2 and 85nsp1bR3 for fragment D1, 85nsp1F2 and 85nsp1bR4 for D2, 85nsp1bF3 and 85nsp1R2 for D3, and 85nsp1bF4 and 85nsp1R2 for D4 (Table 1) . These were then cloned into the pCAGEN-FLAG vector. The mutation of G to A at nucleotide 55 in VR-2385 Nsp1␤ was done by sequential PCR. The first-round PCR was done with primers 85nsp1F2 and 2385nt55R (Table 1) for fragment 1 and with 2385nt55F and 85nsp1R2 for fragment 2. The secondround PCR was done with primers 85nsp1F2 and 85nsp1R2 for overlapping PCR on both fragment 1 and 2. The product of the overlapping PCR was cloned into the pCAGEN-HA vector. A mutation of A to G at nucleotide 55 of MLV Nsp1␤ was also performed, in which the primer 2385nt55R was replaced with 2332nsp1R and primer 2385nt55F with 2332nsp1R. The resulting recombinant plasmids were confirmed by restriction enzyme digestion and DNA sequencing.
Western blot analysis. Protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed by Western blotting as described previously (25, 26) . The separated proteins were transferred onto a nitrocellulose membrane and probed with antibodies against phosphorylated STAT1 at tyrosine-701 (pSTAT1) (Millipore, Billerica, MA), KPNA1 (Santa Cruz Biotechnology, Santa Cruz, CA), ubiquitin (Santa Cruz), hemagglutinin (HA; Rockland Immunochemicals, Inc., Gilbertsville, PA), FLAG (Sigma), STAT2 (Santa Cruz), and ␤-tubulin (Sigma). The antibodies bound on the membrane were detected using secondary antibodies conjugated with horseradish peroxidase (Rockland) and were revealed using a chemiluminescence substrate. The chemiluminescence signal was recorded digitally by using a ChemiDoc XRS imaging system (Bio-Rad Laboratories, Hercules, CA). Digital signal acquisition and analysis were conducted using the Quantity One program, version 4.6 (Bio-Rad).
IP. Immunoprecipitation (IP) was conducted as previously described (19, 27) , with some modifications. HEK293 cells were lysed with a lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 0.2 mM EDTA, 2 mM EGTA, 0.5% Igepal CA-630, 10% glycerol, 1 mM sodium vanadate) supplemented with a protease inhibitor cocktail (Sigma). The lysate was clarified by centrifugation at 14,000 ϫ g for 5 min at 4°C. The supernatant was transferred to a new tube and incubated with FLAG antibody (Sigma), followed by incubation with protein G-agarose (KPL, Inc., Gaithersburg, MD). The final pellet from IP was subjected to elusion with Laemmli sample buffer or 100 mM glycine solution, pH 3.0. The IP samples were subjected to Western blotting with antibodies against pSTAT1, ubiquitin, FLAG, and HA. IP with HA antibody and then Western blotting with FLAG antibody were also conducted. To detect ubiquitinated KPNA1, ubiquitin aldehyde (Boston Biochem, Inc., Cambridge, MA), a specific inhibitor of ubiquitin C-terminal hydrolases, was included in the lysis buffer at a final concentration of 2.53 M.
RNA isolation and real-time PCR. Total RNA was isolated from HEK293 and MARC-145 cells with TRIzol reagent (Invitrogen, Grand Island, NY) in accordance with the manufacturer's instructions. Reverse transcription and real-time quantitative PCR (RT-qPCR) were conducted as previously described (28, 29) . The real-time PCR primers for KPNA1 are KPNA1F1 and KPNA1R1 (Table 1) . Primers for ISG15 and ISG56 were reported previously (19) . Transcripts of ribosomal protein L32 (RPL32) were also amplified and used to normalize the total input RNA. The transcript levels were quantified by the 2 Ϫ⌬⌬CT threshold cycle method (30) and are shown as fold changes relative to the levels of the mock-treated control.
IFA and confocal fluorescence microscopy. Cells were seeded onto coverslips, incubated overnight, and transfected. Immunofluorescence assay (IFA) with monoclonal antibodies against HA or FLAG was done as described previously (31) . The coverslips were mounted onto slides using Fluoromount-G clear mounting medium containing 4=,6=-diamidino-2-phenylindole (DAPI) (Southern Biotech, Birmingham, AL). Confocal fluorescence microscopy was done as described previously (32) .
Statistical analysis. Differences in indicators between treatment groups, such as cellular RNA levels for infection by different virus strains, were assessed using the Student t test. A two-tailed P value of less than 0.05 was considered significant.
RESULTS

PRRSV
Nsp1␤ reduces STAT1/KPNA1 complex after interferon stimulation. The Nsp1␤ of PRRSV VR-2385 was shown to block the IFN-activated nuclear translocation of ISGF3 (19) . Here, the mechanism of inhibition was further examined. STAT1 nuclear translocation mainly involves KPNA1, which functions as an adaptor protein to bind karyopherin-␤ in transferring proteins from the cytoplasm into the nucleus. Initially, we tested whether the interaction of STAT1 and KPNA1 was affected in cells with Nsp1␤ expression. HEK293 cells were transfected with plasmids encoding VR-2385 Nsp1␤-HA, KPNA1-FLAG, and STAT1-GFP. IFN-␣ was added to the cells to activate the JAK/STAT signaling pathway 48 h after the transfection. The cells were then harvested for immunoprecipitation with FLAG antibody. Next, Western blotting was conducted with antibodies against tyrosine-phosphorylated STAT1 (pSTAT1). The blotting results revealed that there was significantly less pSTAT1/KPNA1 complex in cells with Nsp1␤ expression than in cells with empty vector (Fig. 1A) . Western blotting of whole-cell lysates showed similar levels of pSTAT1 in the cells with or without Nsp1␤ expression, whereas the KPNA1 levels in cells with Nsp1␤ were lower than the KPNA1 levels in control cells (Fig. 1A) . MLV Nsp1␤ did not appear to block IFN-activated STAT1/ STAT2 nuclear translocation (19) and was included as a control to test whether it would have any effect on the interaction between STAT1 and KPNA1. IP and Western blotting showed that the pSTAT1 levels in cells with MLV Nsp1␤ were similar to the pSTAT1 levels in control cells (Fig. 1B) . Western blotting of whole-cell lysates showed that the cells with MLV Nsp1␤ had levels of pSTAT1 and KPNA1 that were similar to the levels in control cells. These results indicate that VR-2385 Nsp1␤ reduced pSTAT1/KPNA1 complexes in cells after IFN stimulation, whereas MLV Nsp1␤ did not.
VR-2385 Nsp1␤ reduces KPNA1, and the ubiquitin-proteasome pathway is involved in KPNA1 reduction. We noticed that cells with VR-2385 Nsp1␤ expression had lower KPNA1 levels (Fig. 1A, WCL) . To confirm this, we tested whether Nsp1␤ caused a reduction in KPNA1. HEK293 cells were transfected with plasmids expressing Nsp1␤ of VR-2385, VR-2332, and MLV. Western blotting showed that the KPNA1 levels in cells with Nsp1␤ of VR-2385 or VR-2332 were reduced but that KPNA1 levels in cells with MLV Nsp1␤ changed minimally in comparison to the levels in cells with empty vector (Fig. 2A) . The relative KPNA1 levels were 0.44-, 1.18-, and 0.34-fold for cells with Nsp1␤s of VR-2385, MLV, and VR-2332, respectively. VR-2385 Nsp1␤ was also tested to determine its effect on other KPNAs to exclude the possibility of a nonspecific effect on KPNA1. HEK293 cells were cotransfected with Nsp1␤ and a plasmid expressing KPNA1, KPNA2, KPNA3, or KPNA4. Compared to the results for cells with the empty-vector control, Nsp1␤ reduced KPNA1 considerably but had minimal effects on the other three KPNAs (Fig. 2B) . The results confirmed that Nsp1␤ specifically reduced KPNA1 levels.
Furthermore, when incremental amounts of VR-2385 Nsp1␤ plasmid DNA were used in transfections, the KPNA1 protein levels were reduced in a dose-dependent manner (Fig. 2C) . Densitometry analysis showed that, in comparison with the results for the empty-vector control, the KPNA1 levels were reduced from 0.88-to 0.4-fold in the cells transfected with 0.125 to 1 g of Nsp1␤ plasmid DNA (Fig. 2D) . The Nsp1␤ level increased along with the incremental amount of the plasmid DNA used in the transfection. The results suggested that the Nsp1␤-mediated reduction of KPNA1 was specific. We reasoned that the KPNA1 reduction could be due to a decrease of transcription and/or translation and accelerated protein degradation. To determine the mRNA levels of KPNA1 in the cells with Nsp1␤ expression, we conducted RT-qPCR. The mRNA levels of endogenous KPNA1 in cells with and without Nsp1␤ expression were similar (Fig. 3A) . The results indicated that the reduction of KPNA1 protein was not due to a change in its mRNA level. Next, we tested whether the KPNA1 reduction was due to degradation by the ubiquitin-proteasomal pathway. MG132, a proteasome inhibitor, was added to the cells 24 h after Nsp1␤ transfection. The cells were harvested 6 h later for Western blotting. MG132 treatment of cells with the expression of VR-2385 or VR-2332 Nsp1␤ resulted in the restoration of KPNA1 to levels similar to the levels in the cells with empty vector (Fig. 3B) .
Overexpression of KPNA1 was used in the experiments described above. Endogenous KPNA1 was also detected to exclude the possibility that overexpression of Nsp1␤ affected the expression of exogenous KPNA1. In the presence of Nsp1␤, the endogenous KPNA1 level was considerably reduced in comparison with the level in cells treated with the empty-vector control (Fig. 3C ). In addition, MG132 treatment of cells with Nsp1␤ expression restored KPNA1 to a level similar to that in cells with the emptyvector control (Fig. 3C) . These results indicated that the KPNA1 reduction in the cells with VR-2385 Nsp1␤ was due to degradation by the ubiquitin-mediated proteasomal pathway.
VR-2385 Nsp1␤ increases KPNA1 ubiquitination and shortens its half-life. Since MG132 treatment restored KPNA1 levels, we reasoned that the KPNA1 ubiquitination levels in the cells with Nsp1␤ expression would increase. HEK293 cells were transfected with KPNA1-FLAG, ubiquitin-Myc, and VR-2385 Nsp1␤-HA plasmids. The cells were lysed for IP with antibody against FLAG. Western blotting with ubiquitin antibody was then performed to detect ubiquitinated KPNA1. The blotting results showed that ubiquitinated KPNA1 in the cells with Nsp1␤ appeared as a smear, as expected, and that its density was 4.18-fold greater than in the cells transfected with empty vector (Fig. 4A) . (Fig. 4B ), indicating that there was more ubiquitinated KPNA1 in the cells with Nsp1␤ expression. The IgG heavy and light chains were still visible but did not obstruct the view of the other bands. In addition, wholecell lysate was used in the blotting, which showed that the total ubiquitination levels in the cells with Nsp1␤ expression were similar to the levels in control cells (Fig. 4B) . The results indicate that Nsp1␤ did not induce elevation of total ubiquitination in the cells.
As Nsp1␤ increased KPNA1 ubiquitination, we speculated that the half-life of KPNA1 would be shortened. HEK293 cells were transfected with KPNA1-FLAG and VR-2385 Nsp1␤. The cells were treated with a translation inhibitor, cycloheximide, at a final concentration of 100 g per ml 24 h after the transfection. The cells were then harvested at the time points specified below for Western blotting. In the presence of Nsp1␤, the KPNA1 levels decreased at a higher rate than in cells with the empty vector (Fig.  4C) . The KPNA1 level 6 h after the cycloheximide treatment was reduced 0.5-fold in the cells with Nsp1␤ expression, while it remained at 0.9-fold in cells with the empty vector (Fig. 4D) . The expression of Nsp1␤ induced a shortening of the KPNA1 half-life from approximately 21 h to 6 h. The blotting results also showed that the Nsp1␤ half-life was approximately 17 h. This result is consistent with our data showing increased ubiquitination of KPNA1 in the cells with Nsp1␤ expression.
The N-terminal domain of Nsp1␤ appears to be responsible for the induced degradation of KPNA1. To map the domain of Nsp1␤ involved in inducing the degradation of KPNA1, deletion constructs of VR-2385 Nsp1␤ were prepared. Four fragments of Nsp1␤ were cloned into the pCAGEN-FLAG vector (Fig. 5A) . Overexpression of Nsp1␤ truncation constructs in HEK293 cells was confirmed by Western blotting with FLAG antibody (Fig. 5B) . IFA was also conducted to determine the subcellular location of the truncated Nsp1␤s, as full-length Nsp1␤ was shown to mainly distribute in the nucleus 10 h after virus infection (33) . IFA showed that all four truncated Nsp1␤s were distributed in the cytoplasm, while most of the full-length Nsp1␤ was located in the nucleus (Fig. 5C ). All the truncated Nsp1␤s with the exception of D2 had punctate distribution, while D2 displayed more homogenous dissemination.
Endogenous KPNA1 was detected in HEK293 cells with expression of the Nsp1␤ deletion constructs. Western blotting results showed that the cells with Nsp1␤ D1 (amino acids 1 to 155) and Nsp1␤ D2 (amino acids 1 to 95) had considerably lower KPNA1 levels than the cells transfected with empty vector (Fig. 5D ). Densitometry analysis showed that the cells with Nsp1␤ D1 and Nsp1␤ D2 had KPNA1 levels at 0.31-and 0.4-fold, respectively, compared to the KPNA1 levels in cells with empty vector (Fig. 5E) . The KPNA1 levels in the cells with Nsp1␤ D3 (amino acids 55 to 203) and Nsp1␤ D4 (amino acids 95 to 203) were 0.8-and 1.1-fold, respectively, in comparison to the levels in cells with the empty-vector control. Full-length Nsp1␤ was included as a control and, as expected, resulted in lower KPNA1 levels. The results indicate that the amino-terminal domain (amino acids 1 to 55) of Nsp1␤ was correlated with the degradation of KPNA1.
The amino acid valine at residue 19 of Nsp1␤ appears to be correlated with the induction of KPNA1 degradation. The results from the Nsp1␤ deletion constructs showed that the aminoterminal domain was correlated with the degradation of KPNA1. Sequence comparison indicated that two nucleotides differed between the Nsp1␤s of VR-2332 and MLV, nucleotides 55 and 452. The two different nucleotides result in two different amino acids, valine at residue 19 and serine at residue 151 for VR-2332 Nsp1␤ and isoleucine and phenylalanine for MLV Nsp1␤. VR-2385 Nsp1␤ has the same residues as VR-2332 at these two positions. We reasoned that valine-19 in the VR-2385 Nsp1␤ might correlate with the reduction of KPNA1, as it is in the N-terminal domain. Mutagenesis of the VR-2385 Nsp1␤ plasmid was conducted to create a point mutation at nucleotide 55 from G to A, resulting in an amino acid change from valine to isoleucine. DNA sequencing confirmed the nucleotide change from G to A in the mutant Nsp1␤ plasmid.
Western blotting showed that the KPNA1 levels in the cells with the mutant Nsp1␤ of VR-2385 were similar to those found in cells with the empty-vector control (Fig. 6A) . Densitometry analysis showed that the KPNA1 levels in the cells with the Nsp1␤s of VR-2332, MLV, and VR-2385 and the mutant Nsp1␤ of VR-2385 were 0.37-, 0.88-, 0.49-, and 1.18-fold compared to the levels in cells with the empty-vector control (Fig. 6B) . The results demonstrated that the mutant Nsp1␤ with a substitution at nucleotide 55 had no effect on KPNA1 expression, whereas the wild-type Nsp1␤ reduced the KPNA1 level. This indicates that amino acid valine-19 in VR-2385 Nsp1␤ was correlated with KPNA1 degradation in the cells with Nsp1␤ expression.
As the substitution at nucleotide 55 diminished the ability of Nsp1␤ to induce KPNA1 degradation, we reasoned that the mutant Nsp1␤ would be different from wild-type Nsp1␤ in the JAK/ STAT signaling pathway. HEK293 cells were transfected with wild-type and mutant Nsp1␤ plasmids of VR-2385. IFN-␣ was added to the cells 48 h after the transfection. The cells were harvested 10 h after the IFN stimulation for RNA isolation and RTqPCR to determine the transcript levels of ISG15 and ISG56. The results showed that the cells with expression of the mutant Nsp1␤ had transcript levels of ISG15 and ISG56 similar to the levels in cells with empty vector (Fig. 6C ). The cells with wild-type Nsp1␤ had significantly lower levels of ISG15 and ISG56 transcripts, as expected. Western blotting showed that after IFN treatment, the STAT2 protein level was considerably lower in cells with Nsp1␤ expression than in cells with empty vector. Conversely, the cells with mutant Nsp1␤ had STAT2 levels similar to the levels in cells with the empty-vector control (Fig. 6D) .
To confirm the effect of valine-19 on Nsp1␤, we conducted mutagenesis of MLV Nsp1␤ to mutate isoleucine-19 to valine. As expected, the mutant MLV Nsp1␤ reduced KPNA1 levels (Fig. 6E) . Densitometry analysis showed that the KPNA1 level in the cells with mutant MLV Nsp1␤ was 0.5-fold in comparison to the levels in cells with the wild-type Nsp1␤ (Fig. 6F) . These results demonstrated that valine-19 was correlated with Nsp1␤'s reduction of KPNA1 and inhibition of the JAK/STAT signaling pathway.
PRRSV infection reduces endogenous KPNA1. The results described above showed that Nsp1␤s of both VR-2385 and VR-2332 reduced KPNA1 levels. We reasoned that endogenous KPNA1 protein in MARC-145 cells would decrease after PRRSV infection. MARC-145 cells were infected with PRRSV strain VR-2385, MLV, or VR-2332 and were harvested 24 h postinfection (h.p.i.) for Western blotting. Compared to the levels in mockinfected cells, KPNA1 levels in cells infected with VR-2385 and VR-2332 were reduced to 0.48-and 0.65-fold, respectively, while the protein remained at 0.84-fold in the cells infected with MLV (Fig. 7A) . To test whether the KPNA1 mRNA level in MARC-145 cells changed after PRRSV infection, RT-qPCR was conducted. The results showed that KPNA1 transcripts in the cells with PRRSV infection had no significant difference from those in control cells (Fig. 7B) . PRRSV genomic RNA was also detected in the cells with PRRSV infection. The cells infected with MLV produced significantly more copies of viral RNA than cells infected with the other two strains (Fig. 7C) . As expected, MLV replicated faster than the other two strains in MARC-145 cells.
To test the kinetics of KPNA1 expression after PRRSV infection, we infected MARC-145 cells with VR-2385 and harvested the cells at 16, 24, and 38 h.p.i. Compared to the levels in mock- infected cells, the KPNA1 levels in the virus-infected cells were reduced at 16 h.p.i. and were considerably decreased at 24 and 38 h.p.i. (Fig. 7D) . The Nsp1␤ expression increased with extension of infection time. Densitometry analysis showed that the KPNA1 levels at 16, 24, and 38 h.p.i. were 0.77-, 0.48-, and 0.48-fold, respectively, compared to the levels in mock-infected cells at 16 h.p.i. The results showed that KPNA1 was reduced in the PRRSVinfected cells, which is consistent with our data from Nsp1␤ overexpression.
DISCUSSION
Previous data show that PRRSV inhibits the ability of type I IFNs to induce an antiviral response in MARC-145 and PAM cells and that Nsp1␤ is involved in the inhibition (19) . In this study, the mechanism for Nsp1␤-mediated inhibition of the JAK/STAT signaling pathway was examined. The increased degradation of KPNA1 appears to be the reason, and valine-19 in Nsp1␤ is correlated with the change in KPNA1 levels. Several lines of evidence were provided in this study to support the conclusion. First, Nsp1␤ leads to lower levels of exogenous overexpressed KPNA1. The interaction of pSTAT1 with KPNA1 after IFN stimulation was examined. The cells with Nsp1␤ expression had smaller amounts of pSTAT1/KPNA1 complexes. The total levels of pSTAT1 remained unchanged, while the total KPNA1 levels were reduced in the cells with Nsp1␤ expression. MLV Nsp1␤ did not affect the KPNA1 level or KPNA1 interaction with pSTAT1, which is consistent with the previous data showing that MLV Nsp1␤ does not inhibit pSTAT1 nuclear translocation (19) .
KPNA1 degradation appeared to be due to the ubiquitin-mediated proteasome pathway. Nsp1␤ induced KPNA1 degradation in a dose-dependent manner. The mechanism for the KPNA1 reduction was explored at the mRNA and protein levels. The KPNA1 transcript levels changed minimally in the cells with Nsp1␤ expression. Blocking the ubiquitin-mediated proteasomal degradation pathway with MG132 resulted in the restoration of KPNA1 levels in the cells with Nsp1␤. These results indicated that the proteasome pathway was involved in the Nsp1␤-induced degradation of KPNA1. IP results showed that ubiquitination of KPNA1 in cells with Nsp1␤ expression was significantly increased. Moreover, the KPNA1 half-life was reduced from 21 h to 6 h, which further substantiates the observation of KPNA1 degradation. Since Nsp1␤ reduced KPNA1, we wondered whether it would interact with KPNA1 or not. IP with FLAG antibody to pull down KPNA1-FLAG and then Western blotting with HA antibody failed to detect Nsp1␤-HA (results not shown). Conversely, IP with HA antibody and Western blotting with FLAG antibody did not detect KPNA1-FLAG either. The results indicated that KPNA1 and Nsp1␤ had undetectable or no interaction.
The amino-terminal half of Nsp1␤ contains the functional domain responsible for the KPNA1 degradation. Analysis of the four truncation constructs showed that the N-terminal domain (amino acids 1 to 55) of Nsp1␤ was correlated with the KPNA1 level change. The deletion constructs D1 and D2 contain the Nterminal domain. Their expression resulted in KPNA1 reduction to a level similar to that induced by the full-length Nsp1␤. The deletion constructs D3 and D4 do not have the N-terminal domain, and their expression had minimal effects on KPNA1 levels. Interestingly, all four truncated Nsp1␤s had cytoplasmic distribution, while the full-length Nsp1␤ mainly locates in the nucleus. The results indicate that the cytoplasmic distribution of the fulllength Nsp1␤ was involved in the KPNA1 reduction, as D1 and D2 reduced KPNA1 to levels similar to the level induced by the fulllength Nsp1␤. The cytoplasmic distribution of the four truncated Nsp1␤s also indicates that the nuclear localization signal of Nsp1␤ was disrupted in the short fragments. Crystallization of Nsp1␤ showed that amino acids 1 to 48 comprise a nuclease domain, amino acids 49 to 84 the linker domain, amino acids 85 to 181 a papain-like cysteine protease (PCP) domain, and amino acids 182 to 203 the C-terminal extension (34) . Our results showed that the N-terminal nuclease domain of Nsp1␤ correlates with the KPNA1 degradation, indicating that the domain has additional functions. A recent report also showed that the nuclease domain of Nsp1␤ correlates with inhibition of type I IFN induction (35) .
Valine-19 of Nsp1␤ is associated with the KPNA1 degradation. A mutation at nucleotide 55 from G to A diminished VR-2385 Nsp1␤'s ability to inhibit the JAK/STAT signaling pathway. Both VR-2385 and VR-2332 reduced KPNA1, while MLV did not. There were only two nucleotides that differed between the VR-2332 and MLV Nsp1␤s, which were potentially associated with the KPNA1 reduction. Nucleotide 55 was selected for mutagenesis because the amino-terminal domain (amino acids 1 to 55) was found to correlate with KPNA1 reduction. Interestingly, the amino acid change from valine to isoleucine in VR-2385 Nsp1␤ abolished its ability to reduce KPNA1. Expression of this mutant VR-2385 Nsp1␤ in HEK293 cells had little effect on IFN-activated JAK/STAT signaling. Conversely, the amino acid change from isoleucine to valine in MLV Nsp1␤ caused reduction of KPNA1. These results indicate that valine-19 is important for the Nsp1␤-induced degradation of KPNA1. The mutation from valine to isoleucine might affect the interaction of Nsp1␤ and an unknown protein that leads to the ubiquitination of KPNA1. A lysine and a serine are the residues immediately upstream and downstream from valine-19. Common posttranslational modifications, including methylation, ubiquitination, and phosphorylation, often occur on these two amino acids in many proteins. Thus, they might play a bigger role in the interaction of Nsp1␤ and the unknown protein. The presence of valine or isoleucine between these two amino acids might lead to different conformations in the Nsp1␤ domain. Sequence alignment revealed that residue 19 of Nsp1␤s is either valine or isoleucine, which are highly conserved across the strains in type 2 PRRSV (data not shown). The stretch of residues around valine-19 has also been shown by a recent report to be involved in inhibition of type I IFN induction (35) . Residues 16 to 20 of Nsp1␤ were mutated to alanine in an infectious cDNA clone, and the mutant virus recovered was able to induce higher levels of type I IFN transcripts in infected macrophages. However, the nuclease or protease activity of Nsp1␤ seems to be unrelated to its ability to enhance KPNA1 ubiquitination, because Nsp1␤s of VR-2332 and MLV have only two different amino acids that do not affect nuclease or protease activity (34, 36) . Nsp1␤ is the second of the nonstructural proteins encoded by PRRSV ORF1a and has drawn attention due to its ability to inhibit interferon induction and IFN-activated JAK/STAT signaling (19, 33, 35, 37, 38) , interact with cellular poly(C) binding protein (39) , and suppress tumor necrosis factor alpha promoter activation (40) .
PRRSV infection leads to a reduction of endogenous KPNA1. KPNA1 levels were reduced in the cells infected with VR-2385 and VR-2332, but MLV replication did not reduce KPNA1 levels. The KPNA1 reduction was not due to KPNA1 mRNA changes, as cells infected with different strains had similar levels of KPNA1 mRNA transcripts. Kinetic studies of KPNA1 levels confirmed the KPNA1 reduction in the virus-infected cells. The results indicate that Nsp1␤ may play a role in the inhibition of IFN-activated signaling in the virus-infected cells.
KPNA mediates the nuclear import of many cytoplasmic proteins (41, 42) . KPNA1 is essential to the nuclear transport of phosphorylated STAT1 (43) . Therefore, KPNAs have been targeted by some viruses to interfere with IFN-activated JAK/STAT signaling. For example, Ebola virus VP24 binds KPNA1 and blocks pSTAT1 nuclear translocation (27, 44) . VP24 interacts with KPNA1 in the region overlapping with pSTAT1. The ORF6 product of severe acute respiratory syndrome coronavirus disrupts nuclear import of pSTAT1 by tethering KPNA2 to the endoplasmic reticulum/ Golgi membrane (45) .
The E3 ubiquitin ligase for KPNA1 degradation is not known, although RAG1 ubiquitin ligase was reported to interact with KPNA1 (46) . RAG1 is also a recombinase involved in DNA rearrangement of immunoglobulin and T-cell receptor genes in B and T lymphocytes. KPNA1 is a putative substrate of RAG1 (46) , but degradation of KPNA1 was not demonstrated. In addition, RAG1 distribution could be limited to the immune cells. Thus, RAG1 is not likely to be the Nsp1␤-targeted E3 ligase for KPNA1 ubiquitination and proteasomal degradation. Our IP did not detect interaction between Nsp1␤ and KPNA1, which excluded the possibility of Nsp1␤ as an E3 ligase. Further work is needed to identify the E3 ligase for the Nsp1␤-mediated KPNA1 degradation.
In conclusion, the mechanism of PRRSV Nsp1␤ inhibition of JAK/STAT signaling was discovered in this study. Nsp1␤ induced degradation of either overexpressed or endogenous KPNA1. PRRSV infection of MARC-145 cells led to lower KPNA1 levels. The presence of valine-19 in the N-terminal domain of Nsp1␤ was found to correlate with the KPNA1 degradation. This is the first report that a viral protein targets cellular importin for degradation. Our study provides further insight into PRRSV interference with the IFN-mediated antiviral response.
